| Z |
| Za T. |
- |
Risk for recurrent venous thromboembolism after a first superficial vein thrombosis among carriers of inherited thrombophilia |
| |
- |
Inherited thrombophilia and associated risk for unexplained fetal loss |
| |
- |
Risk for venous thrombosis in unusual sites associated with inherited thrombophilia: analysis of 133 patients |
| |
- |
Risk for venous thromboembolism among younger or older carriers of inherited thrombophilia |
| Zabe M. |
- |
Translocation of plasma membrane Ca2+-ATPase to filopodia during platelet activation |
| Zacharof A. |
- |
Anti-phospholipid syndrome in systemic lupus erythematosus |
| Zacharof H. |
- |
Anti-phospholipid syndrome in systemic lupus erythematosus |
| Zacharof L. |
- |
Anti-phospholipid syndrome in systemic lupus erythematosus |
| Zacharski L. R. |
- |
Reducing body iron stores lowers inflammatory cytokine levels in atherosclerotic claudicants |
| Zacharski L. R. |
- |
P-selectin-dependent lung colonization of melanoma cells is targeted by heparin treatment |
| Zacharski L. R. |
- |
Correlation of the serum ferritin (SF) levels with cholesterol and body mass index (BMI) in patients with advanced atherosclerosis |
| Zadro R. |
- |
Comparative evaluation of four rapid quantitative D-dimer assays |
| Zadro R. |
- |
The combination of lupus anticoagulant sensitive and insensitive aPTT reagent together with dRVVT screening reagent for the exclusion of the presence of lupus anticoagulant |
| Zago M. A. |
- |
A functional single-nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) associated with risk and outcome of meningococcal disease (MD) |
| |
- |
A 23-bp insertion in the EPCR gene and the risk of venous thrombosis |
| |
- |
Factor XIII (FXIII) Val34Leu, His95Arg and G30899A polymorphisms and the risk of deep venous thrombosis |
| |
- |
A transcobalamin gene polymorphism and the risk of deep venous thrombosis |
| Zaharaki A. |
- |
Correlation SVCAM, SICAM plasma levels with the outcome of treadmill test and with attitudinal factors for coronary artery disease in patients without previous history of ischemic heart disease |
| |
- |
Levels of plasma tissue activator plasminogen (tPA)- A useful marker in the differential diagnosis of chest pain (marker of plaque destabilization) |
| |
- |
Obesity and coagulation. Is there any correlation? |
| |
- |
Inflammatory factors in patients with acute coronary syndromes. Is there any fluctuation with smoking or cholesterol levels? |
| |
- |
Is there an hypercoagulable state after treadmill exercise in patients with atrial fibrillation? |
| |
- |
Smoking and abnormalities of coagulation-fibrinolysis in patients with coronary heart disease |
| |
- |
Correlation between SVCAM, SICAM plasma levels, the outcome of treadmill test and the systolic function of left ventricular (LV) in patients with coronary artery disease |
| Zahler S. |
- |
Magnetofection – a highly efficient tool for endothelial gene transfer and antisense oligonucleotide delivery in vitro and in vivo |
| Zahrani H. |
- |
Single center review of clinicopathological characterization in 77 patients with positive lupus anticoagulant antibodies |
| Zaid D. |
- |
The mannometric profile of native arteriovenous fistulas in the Avicenne Hemodialysis Center of Casablanca (preliminary results) |
| Zalavras C. |
- |
Mutations of the methylenetetrahydrofolate reductase (MTHFR) gene and osteonecrosis. A preliminary report |
| Zalavras C. |
- |
Is the G455A polymorphism of the fibrinogen beta gene associated with osteonecrosis? A preliminary report |
| Zalepouchina O. |
- |
Red blood cells ABH and Lewis antigens prevalence in von Willebrand disease patients |
| Zamagni E. |
- |
Venous thromboembolic complications in patients with multiple myeloma treated with thalidomide:prophylatic effect of fixed dose Wafarin L |
| Zamboni P. |
- |
The G>T point mutation (Val34Leu) in the Factor XIII-A subunit gene in venous leg ulcers |
| Zamd M. |
- |
The mannometric profile of native arteriovenous fistulas in the Avicenne Hemodialysis Center of Casablanca (preliminary results) |
| Zamora-Gonzalez J. |
- |
Lipoprotein (a) polymorphisms in Mexican-Amerindian populations |
| Zampolli A. |
- |
Statins inhibit cyclo-oxygenase (cox)-2 and metalloproteinase (mmp)-9 expression in human endothelial cells: possible contribution to plaque stability |
| Zanardo G. |
- |
Contemporary total hip and knee replacement in A patients with haemophilia and high titre of inhibitors to FVIII by using recombinant FVIIa (novoseven) continuous infusion |
| |
- |
Management of oral anticoagulant therapy in the perioperative period: preliminary results of the application of an operative protocol |
| Zanazzi M. |
- |
Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal transplant recipients |
| Zander A. R. |
- |
Use of recombinant factor VIIa in severe acquired coagulopathies in childhood |
| Zandstra D. F. |
- |
Lepirudin anti-coagulation in critically ill patients with (suspected) heparin-induced thrombocytopenia and thrombosis |
| Zanna D. |
- |
Increased procoagulant activity and impaired fibrinolytic potential in blood mononuclear cells after coronary angioplasty for stable or unstable angina |
| Zanon E. |
- |
Factor VII deficiency associated with severe hemophilia A |
| Zanon E. |
- |
Anti-prothrombin antibodies in patients with recurrent venous thromboembolism |
| Zarzur J. |
- |
Development, scale up and characterization of the first regional high purity Factor VIII: the Argentinean experience |
| Zarzur J. A. |
- |
Preparation of prothrombin complex concentrate (PCC) at intermediate scale: first experience in Argentina |
| Zavalova L. |
- |
Proposed mechanisms of thrombolytic action of the medicinal leech saliva |
| Zavalova L. L. |
- |
Anti-hemostasis stimulated by the medicinal leech application as a result of mast cells activation by the leech saliva |
| Zawadsky C. |
- |
Three abnormal patterns for inversion breaking intron 1 of the FVIII gene |
| Zawadzki C. |
- |
Effect of in vivo thrombin inhibition on bFGF-induced angiogenesis in a murine angiogenic model |
| |
- |
Tissue factor pathway in carotid atherosclerotic plaques: relationships with clinical patterns and risk factors |
| |
- |
Tissue factor predicts long-term outcome after percutaneous coronary revascularization |
| Zawilska K. |
- |
High frequency of combined genetic prothrombotic defects in young patients with ischemic stroke |
| |
- |
Thrombin activable fibrinolysis inhibitior (TAFI) in patients with obesity |
| |
- |
The influence of Percutaneous Transluminal Coronary Angioplasty (PCTA) in patients with stable angina on the inflammation markers, lymphocyte activation and platelet-leukocyte aggregates in peripheral venous blood |
| |
- |
Antiphospholipid antibodies in patients diagnosed for thrombophilia |
| Zdziarek J. |
- |
Fibrinolytic activity of venous endothelium in postphlebitic syndrome |
| Zehnder J. L. |
- |
Intrauterine growth retardation and recurrent pregnancy loss associated with prothrombin gene variants 20221C > T and 20209C > T |
| |
- |
Novel factor V mutations in three separate families resulting in factor V deficiency and bleeding |
| Zeinali S. |
- |
Prenatal diagnosis of dysprothrombinemia in an Iranian family |
| |
- |
Rapid screening of factor IX mutations by SSCP and sequencing in 50 Iranian families |
| |
- |
Rapid analysis of the HindIII/intron 19 polymorphism within the human factor VIII gene by ARMS/PCR method |
| Zeinali S. |
- |
Prenatal diagnosis of hemophilia A in the only governmental center for prenatal diagnosis in IRAN |
| Zeinali M. |
- |
Prenatal diagnosis of hemophilia A in the only governmental center for prenatal diagnosis in IRAN |
| Zeinali S. |
- |
Psychosocial aspects of inherited bleeding disorders among Iranian patients |
| |
- |
Reporting presence of 9 novel mutations in hemophilia B patients in Iran |
| Zeiner A. |
- |
High prevalence of aspirin resistance in patients with acute coronary syndromes |
| Zelcer S. |
- |
Thrombosis in patients with immune thrombocytopenic purpura (ITP): a case series |
| Zenz W. |
- |
Variation in plasminogen activator inhibitor-1 gene and risk of meningococcal disease |
| Zeratti E. A. |
- |
Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis |
| Zerbinati P. |
- |
The incidence of venous thromboembolism in carriers of single identified prothrombin G20210A: a retrospective cohort study |
| |
- |
Correlation between internal carotid artery stenosis and hematological risk factors for thrombosis (CAST study): final results |
| |
- |
Levels of anti-thrombin III activity in the plasma of cynomolgus monkeys after administration of recombinant human anti-thrombin III |
| |
- |
Incidence of recurrent ischemic stroke in children with coagulation abnormalities |
| |
- |
Anti-thrombin III levels in cynomolgus monkey recipients of a life-supporting porcine renal xenograft |
| |
- |
The incidence of venous thromboembolism in double-heterozygous carriers of antithrombin, protein C and protein S deficiency and HR2 haplotype |
| |
- |
The incidence of venous thromboembolism in homozygous or double heterozygous carriers of the factor V Leiden mutation, prothrombin 20210 A mutation and HR2 aplotype: interim report |
| Zervas K. |
- |
Effect of rFVIIa (NovSeven®) on thrombin generation in patients with severe thrombocytopenia |
| Zewald R. A. |
- |
The relation between clinical phenotype and genotype of severe hemophilia A |
| Zhai W. |
- |
Soluble platelet GPV: a new marker of thrombosis status |
| Zhai Z. |
- |
Increased fibronectin secretion but not cell surface expression in thrombin-activated platelets of hypofibrinogenemia patients |
| Zhang W. |
- |
A novel point mutation in the transmembrane domain of the platelet glycoprotein IX associated with bernard–soulier syndrome |
| Zhang B. |
- |
MCFD2, a second gene defective in combined factor V/factor VIII deficiency, encodes a novel ER protein that interacts with LMAN1 (ERGIC-53) to form a cofactor-specific sorting receptor |
| Zhang C. |
- |
Transgenic mice studies demonstrate a role for platelet factor 4 (PF4) in thrombosis: implications for heparin-induced thrombocytopenia (HIT) |
| |
- |
Murine (m) aIIb out-competes human (h) aIIb for mouse b3 in a transgenic mouse model: Implications for integrin subunit interactions |
| Zhang K. |
- |
Mechanisms of homeostasis of blood coagulation factors |
| Zhang C. |
- |
Evaluation of IgG formation to trace mammalian proteins in hemophilia patients treated with a recombinant therapeutic protein preparation |
| Zhang W. |
- |
Thrombin activates the cGMP-inhibited cAMP-dependent phosphodiesterase (PDE3A) in platelets |
| Zhao Z. |
- |
Development of small molecule compounds that inhibit PAI-1 activity in vitro and in vivo |
| Zhao J. |
- |
Limited exposure of phosphatidylserine on stimulated platelets is necessary for procoagulant activity and provides binding sites for lactadherin |
| Zhao L. |
- |
Platelet–leukocyte interactions in the presence of GPIIb-IIIa antagonists, and a combination of aspirin, dipyridamole and AR-C69931 |
| |
- |
The effects of three anti-platelet drugs (aspirin, clopidogrel, dipyridamole) given singly or together on platelet and leukocyte function in healthy subjects and patients with previous ischemic stroke |
| Zhao L. |
- |
Activated platelets and platelet-derived microvesicles (PMV) transfer tissue factor (TF) to monocytes but not to neutrophils |
| Zhao X. |
- |
A novel point mutation in the transmembrane domain of the platelet glycoprotein IX associated with bernard–soulier syndrome |
| Zhao B.-Q. |
- |
Increased expression of endogenous tissue-type plasminogen activator and matrix metalloproteinase 9 contribute to heparin-produced cerebral hemorrhage after focal cerebral ischemia in mice |
| Zharkova T. |
- |
Efficacy of 1-year acenocumarol therapy and its relation with gene polymorphism related to thrombophilia in patients with nonvalvular atrial fibrillation |
| Zhauchao Y. |
- |
Simultaneous occurrence of lupus anticoagulant and factor VIII inhibitors in hyperththyroisis |
| Zheng S. |
- |
Multimerin supports platelet adhesion by functioning as an RGD ligand for platelet integrin receptors |
| Zheng H. |
- |
Combined carrier status of prothrombin 20210 A and factor XIII-A L34 alleles as a strong risk factor for myocardial infarction: evidence of a gene–gene interaction |
| Zhimin Z. |
- |
The clinical significance of TpP in patient with acute coronary syndrome |
| Zhong D. |
- |
Characterization of a monoclonal antibody to factor VIII: epitope mapping and mechanism of inhibition |
| Zhou Q. |
- |
Copper binding site(s) in factor VIII involved in the regulation of cofactor specific activity |
| Zhou A. |
- |
Measurement of the in-vitro half life and the pathological significance of the transition of anti-thrombin to the latent state |
| Zhou H. |
- |
The epidemiology of venous thromboembolism in California |
| |
- |
Effect of age on the incidence of venous thromboembolism after surgery |
| Zhou H. |
- |
Inhibition of anti-phospholipid antibody-induced monocyte tissue factor activity by dipyridamole and dilazep: role of adenosine |
| Zhou Q. |
- |
Evidence that interaction of the A2 domain of factor VIIIa with factor IXa occurs over an extended surface |
| Zhou H. |
- |
Cell surface annexin A2 (ANX2) mediates the up-regulation of monocyte tissue factor activity by b2-glycoprotein I (b2GPI) and anti-b2GPI autoantibodies |
| Zhou L. |
- |
Preparation of special proteome chip and the application in primary screening of antigens of clotting factors of clinical plasma specimens |
| Zhou A. |
- |
How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration |
| Zhu X. Y. |
- |
A chimeric anti-human tissue factor antibody attenuates inflammatory responses in rhesus monkeys challenged with E. coli |
| Zhu H. |
- |
A recombinant von Willebrand factor fragment inhibits binding of von Willebrand factor to glycoprotein Ib-IX |
| Zhu H. |
- |
Dominant negative anticoagulant effects of mouse recombinant meizothrombin precursor R157A/R268A delay thrombus formation in a mouse injured carotid artery |
| |
- |
A transgenic mouse model demonstrates the efficacy of Factor VIII ectopically expressed in platelets for Haemophilia A treatment |
| Ziakas G. |
- |
Congenital defect of inferior vena cava and thrombophilia Leiden |
| Zibara K. |
- |
Structural and functional characterization of a new transcription factor (6A3-5) potentially implicated in changes of smooth muscle cells phenotype |
| Zibis A. H. |
- |
Mutations of the methylenetetrahydrofolate reductase (MTHFR) gene and osteonecrosis. A preliminary report |
| |
- |
Is the G455A polymorphism of the fibrinogen beta gene associated with osteonecrosis? A preliminary report |
| Zidane M. |
- |
A prospective implementation study of out-patient treatment with subcutaneous low-molecular-weight heparin and oral anti-coagulants in patients with deep venous thrombosis in routine clinical practice |
| Zieger B. |
- |
Insufficient F IX-recovery after treatment with recombinant F IX compared to plasma-derived F IX |
| Zieger B. |
- |
Sinus venous thrombosis in children – a multifactorial etiology |
| Ziegler H. |
- |
A rapid chromogenic method for determination of TAFI in plasma samples |
| Zieleniewska B. |
- |
Immune tolerance induction in the treatment of children with haemophilia A complicated by factor VIII inhibitor |
| Zielinski J. |
- |
Compression ultrasound in diagnosis of asymptomatic deep venous thrombosis |
| Ziemer S. |
- |
Recombinant PrPP102L stimulates t-PA mediated plasminogen activation 4-fold stronger than recombinant wild-type PrPc |
| Zieseniss S. |
- |
Microvesicle and platelet associated tissue factor promote initiation of coagulation |
| Zighetti M. L. |
- |
Inherited thrombophilia and hyperhomocysteinemia in upper limb deep vein thrombosis |
| |
- |
Does plasma homocysteine influence the in vitro anti-coagulant response to activated Protein C? |
| Zimmerman T. |
- |
In vitro assessment of inhibitory potential of plasma and whole blood toward exogenous plasmin |
| Zimmermann K. |
- |
Surface exposed mutation W2313A in the C2-domain of FVIII results in defective secretion of otherwise functional protein |
| Zimmermann R. |
- |
The development of inhibitors directed against factor VIII after continuous infusion of factor VIII concentrates in patients with hemophilia A |
| Zimmermann K. |
- |
Towards the development of a recombinant von Willebrand factor-cleaving protease (ADAMTS-13) |
| Zimmermann M. |
- |
Platelet receptor polymorphism HPA-1b and the G20210A mutation of the prothrombin-gene are risk determinants of vascular access thrombosis in hemodialysis patients |
| Zimmermann K. |
- |
ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS-13 |
| Zingale G. |
- |
Preparation of prothrombin complex concentrate (PCC) at intermediate scale: first experience in Argentina |
| |
- |
Development, scale up and characterization of the first regional high purity Factor VIII: the Argentinean experience |
| Zivelin A. |
- |
The severely impaired thrombin generation in 5 patients with severe factor XI deficiency and inhibitors is corrected in vitro by recombinant factor VIIa |
| |
- |
Aging of ancestral mutations causing factor VII deficiency and Dubin–Johnson syndrome in Iranian and Moroccan Jews reflects ancient Jewish migrations |
| Zivelin A. |
- |
Substitutions of conserved Gly193 (numbering according to chymotrypsin) located near the catalytic triad of factors VII, IX and XI yield dysfunctional proteins probably due to interference with accessibility of the respective substrates |
| |
- |
Cys61stop is the first identified nonsense mutation in the factor X gene causing severe factor X deficiency in 3 unrelated homozygotes of Arab origin |
| Zivkovic M. |
- |
Comparative evaluation of four rapid quantitative D-dimer assays |
| Zlokovic B. V. |
- |
Protein S confers neuronal protection during ischemic/hypoxic injury in mice |
| |
- |
Recombinant murine activated protein C is neuroprotective in a murine ischemic stroke model |
| |
- |
Activated protein C (APC) blocks p53-mediated apoptosis in ischemic human brain endothelium through endothelial protein C receptor (EPCR) and protease activated receptor 1 (PAR-1) |
| |
- |
In vivo activated protein C (APC) neuroprotective activity involves endothelial protein C receptor (EPCR) and protease activated receptor 1 (PAR-1) |
| Zogg M. |
- |
Altered vascular remodeling in hyperfibrinogenemic mice |
| |
- |
Platelets and fibrinogen are not required for embryonic development but have distinct roles for placentation |
| Zoghlami-Rintelen C. |
- |
Is inflammation involved in the development of thrombosis in patients with the lupus anticoagulant? |
| Zoghlami-Rintelen C. |
- |
IgG-antibodies (IgG-Ab) against beta-2-glycoprotein I (b2-GPI) are associated with an increased risk for thrombotic events (TE) in patients (pts) with the lupus anticoagulant (LA) |
| Zografidis T. |
- |
Population pharmacokinetics of the ReFacto coagulation factor VIII in clinical hemophilia patients with HIV |
| Zoller N. |
- |
Triglycerides show an immediate increase during anticoagulant therapy for DVT without increase in thrombin generation |
| Zollman A. |
- |
Examining the role of coagulation Factor VII using FVII-insufficient mice |
| Zollner T. M. |
- |
P-selectin-dependent lung colonization of melanoma cells is targeted by heparin treatment |
| Zolotarova E. |
- |
Both shear and temperature can profoundly alter antithrombotic drug efficacy: demonstration with the P2Y12 ADP receptor antagonist, ARC-69931MX |
| Zomas A. |
- |
Early therapeutic splenectomy may reduce morbidity and management costs in selected resistant or relapsing cases of TTP/HUS |
| Zonzin P. |
- |
Long-term clinical outcome of patients with pulmonary embolism: a prospective, multicenter study |
| |
- |
Incidence of newly diagnosed cancer after three months or one year of oral anticoagulation for a first episode of idiopathic venous thromboembolism |
| Zorio E. |
- |
Lipoprotein (a) levels and isoforms and fibrinolytic parameters in young survivors of myocardial infarction with and without peripheral artery disease |
| Zotz R. B. |
- |
High levels of plasma markers of coagulation factors (I, VIII:C, XI, XII), inflammation, and hyperhomocysteinemia are risk determinants of pre-eclampsia and HELLP syndrome |
| Zotz R. |
- |
A multinational observational cohort study in hospitalized medical patients of practices in prevention of venous thromboembolism and clinical outcomes: findings of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) |
| Zotz R. B. |
- |
High levels of plasma markers of coagulation factor VIII:C and von Willebrand factor are independent risk determinants of pregnancy-associated venous thromboembolism |
| Zotz R. |
- |
Lipid levels and homocysteine are determinants which influence the epinephrine–collagen- and ADP–collagen-closure time |
| Zotz R. B. |
- |
Influence of anti-thrombin on platelet adhesion onto immobilized fibrinogen in simulated low flow in vitro system |
| Zotz R. |
- |
Platelet receptor polymorphism HPA-1b and the G20210A mutation of the prothrombin-gene are risk determinants of vascular access thrombosis in hemodialysis patients |
| Zotz R. B. |
- |
Rapid induction of immune tolerance with von Willebrand factor containing factor VIII concentrate in acquired hemophilia A |
| Zotz R. B. |
- |
Platelet receptor polymorphisms of glycoprotein (GP) Iba VNTR, GP IIb-IIIa (HPA–1), and GP Ia C807T and the risk of premature myocardial infarction |
| Zouaoui Boudjeltia K. |
- |
The biphasic waveform of APTT optical clot formation profile is related with the activation of FVII but not with ISTH DIC score or classical coagulation activation parameters |
| |
- |
A new Global Plasma Fibrinolytic Assay for the rapid analysis of hyper-/hypo-Fibrinolysis: relationship with blood lipids and inflammatory markers |
| Zovko V. |
- |
Comparative evaluation of four rapid quantitative D-dimer assays |
| Zozulinska M. |
- |
Antiphospholipid antibodies in patients diagnosed for thrombophilia |
| Zuber M. |
- |
Genetic polymorphisms and the risk of development of ischemic stroke. Result of a case control study |
| Zubizarreta A. |
- |
Successful use of recombinant FVIIa (Novoseven) for severe bleeding in a patient undergoing bone marrow transplantation refractory to standard hemostatic support |
| |
- |
Recombinant Factor VIIa as hemostatic agent in acquired von Willebrand disease |
| Zucker M. |
- |
A novel recombinant tissue factor assay for measuring the anti-Xa effect of Low-Molecular-Weight Heparin (LMWH): implications for interventional coronary procedures |
| Zucker M. L. |
- |
Safety of low intensity warfarin regimen in Chinese patients With mechanical heart valve prostheses |
| Zucker M. |
- |
Precision of INR (International Normalized Ratio) measurement using laboratory and point-of-care assays: Understanding the impact of system influence on patient management |
| Zuckerman L. A. |
- |
Agreement between FXIII activity assays and calibrator plasma pools: the need for a FXIII reference standard with regulatory recognition |
| Zuckerman L.A. |
- |
A randomized, double-blind, placebo-controlled study of the safety and pharmacokinetics of a single dose of recombinant Factor XIII in healthy volunteers |
| Zuckerman L. A. |
- |
Pharmacokinetics of recombinant human FXIII in cynomolgus monkeys |
| Zufferey P. |
- |
A meta-analysis on the benefit-to-risk ratio of Vitamin K antagonists (VKA) in the prevention of venous thromboembolism in major orthopedic surgery |
| Zuo Y. |
- |
Inflammatory modulation of alveolar coagulation inhibition in a mouse model of acute respiratory distress syndrome (ARDS) |
| Zurlini C. |
- |
An alternative model for management of oral anticoagulant therapy: role of general practitioners with support of a computerized system and a portable coagulometer |
| Zuurveld M. G. |
- |
A mouse model for inhibitor development in mild hemophilia A |
| Zwaal R. F. A. |
- |
IgG antiprothrombin antibodies from patients with antiphospholipid syndrome inhibit the inactivation of Factor Va by activated protein C |
| Zwaginga J. J. |
- |
a4 integrins and P-selectin mediate rolling and initial attachment of platelet-monocyte complexes to activated endothelium under flow conditions |
| Zwart J. E. F. |
- |
An evaluation of 30 years of hemophilia treatment in the Netherlands |
| Zweegman S. |
- |
Venous thrombosis and APC resistance during hormone treatment in male-to-female transsexuals |
| Zwerts F. |
- |
Endothelial-specific inactivation of survivin in mice results in embryonic lethality with intraembryonic bleeding due to loss of vascular endothelial integrity |
| Zwinge B. |
- |
Association between factor XIII Val34Leu polymorphism and risk of ischemic stroke in young patients |
| |
- |
Important Role of FV G1691A and FII G20210A in women with pregnancy loss without apparent causes |
